It is estimated that 350 million individuals worldwide suffer from rare diseases, which are predominantly caused by mutation in a single gene 1 . The current molecular diagnostic rate is estimated at 50%, with whole-exome sequencing (WES) among the most successful approaches [2] [3] [4] [5] . For patients in whom WES is uninformative, RNA sequencing (RNA-seq) has shown diagnostic utility in specific tissues and diseases [6] [7] [8] . This includes muscle biopsies from patients with undiagnosed rare muscle disorders 6, 9 , and cultured fibroblasts from patients with mitochondrial disorders 7 . However, for many individuals, biopsies are not performed for clinical care, and tissues are difficult to access. We sought to assess the utility of RNA-seq from blood as a diagnostic tool for rare diseases of different pathophysiologies. We generated whole-blood RNA-seq from 94 individuals with undiagnosed rare diseases spanning 16 diverse disease categories. We developed a robust approach to compare data from these individuals with large sets of RNA-seq data for controls (n = 1,594 unrelated controls and n = 49 family members) and demonstrated the impacts of expression, splicing, gene and variant filtering strategies on disease gene identification. Across our cohort, we observed that RNA-seq yields a 7.5% diagnostic rate, and an additional 16.7% with improved candidate gene resolution.
We obtained RNA-seq data from samples from 143 individuals, 94 affected by rare diseases and 49 unaffected family members (Supplementary Table 1) , and WES or whole-genome sequencing for 112 of them. In total, WES did not to identify the causal variant in 88.8% of patients. Patients represented 80 different diseases and were broadly classified into 16 distinct disease categories, with neurology, musculoskeletal, hematology and ophthalmology as the most frequent ( Fig. 1a and Supplementary Table 2 ). We integrated these data with RNA-seq data from healthy individuals from the Depression Genes and Network (DGN) cohort (n = 909) 10 , the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) project (n = 65) 11 and the Genotype-Tissue Expression consortium (GTEx version 7) (n = 620) cohorts 12 (Supplementary  Table 3 ). By comparison with large healthy cohorts, we demonstrate how extreme gene expression and splicing events can aid in identifying candidate genes and variants.
We first evaluated the extent that whole-blood RNA-seq captured gene expression of known rare-disease genes in each major disease category (Fig. 1b and Supplementary Table 4 ). When broadly considering disease genes from the Online Mendelian Inheritance in Man (OMIM) database 13 , we observed that 70.6% were expressed in blood and that 50% of corresponding gene-splicing junctions were covered with at least 5 reads in 20% of samples (Extended Data Fig. 1a,b) . Notably, for a panel of genes known to be involved in neurological disorders (n = 284), we observed that 76% were expressed. Using scores from Exome Aggregation Consortium (ExAC) 14 , we further observed that genes expressed across multiple tissues were Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts Table 3 ). This suggests that mutations that have more severe consequences occur more often in genes for which expression is not restricted to one tissue. Indeed, we observed that 66% of LoF-intolerant genes (probability of being intolerant to LoF mutations (pLI) ≥ 0.9) are expressed in blood samples (average transcripts per million (TPM) ≥ 1) (Extended Data Fig. 1d) .
Outlier (or aberrant) expression of a gene in a sample when comparing with all tested samples has previously been shown to help identify large-effect rare variants and rare-disease genes in blood [15] [16] [17] . We assessed the differences between outlier genes in individuals with disease versus controls after correcting the data for batch effects (see Methods and Extended Data Figs. 2 and 3). We observed an enrichment of case under-expression outliers in genes more sensitive to LoF mutations (Fig. 2a, red) . This observation corroborates previous evidence that new LoF mutations are more likely to lower expression level through nonsense-mediated decay [18] [19] [20] . As we increased the number of controls, the enrichment became stronger, demonstrating the impact of large control data sets (Extended Data Fig. 4) .
We observed an average of 343 outliers per sample (|Z-score| ≥ 2; Fig. 2b ). We tested different variant and gene-level filters that could aid in further narrowing down the lists of candidate genes (Fig. 2c) . We filtered for genes that were LoF intolerant (Filter 1: pLI ≥ 0.9), were likely to have a regulatory variant impacting gene expression (Filter 2: RNA-informed variant effect on regulation (RIVER) score ≥ 0.85 (ref.
21
)), showed allele-specific expression (ASE) (Filter 3), were linked to the phenotype (Filter 4: Human Phenotype Ontology 22 (HPO) match), had a rare variant with minor allele frequency (MAF) ≤ 0.1% within 10 kb upstream of the gene (Filter 5) and had a rare variant that was probably deleterious (Filter 7: Combined Annotation Dependent Depletion (CADD) score ≥ 10). Other filters were combinations of these sets. We observed that when restricting to under-expression outlier genes with HPO matches and a deleterious rare variant nearby, we were able to reduce the candidate genes list to less than 1% of the initial set of outliers with 80% of individuals with disease having at least 1 candidate gene (Filter 11; Fig. 2c and Extended Data Fig. 5a ). Overall, we were able to reduce the number of expression outliers to less than ten on average for all individuals (Fig. 2d) .
Outlier splicing is also an important contributor to Mendelian disease 6, 7, [23] [24] [25] [26] . To evaluate splicing events across rare-disease samples, we corrected junction data for batch effects (Extended Data Fig. 6 ) and obtained Z-scores in all samples ( Fig. 3a and see Methods). On average, we detected 540 splicing outlier genes for each sample at |Z-score| ≥ 2 (Fig. 3b) . We observed that the number of splicing outliers was influenced by the number of junctions in each gene, was higher in individuals with disease and, similar to expression outliers, was enriched in genes sensitive to LoF mutation (data not shown). From both exome and genome data alone, we observed that the number of rare variants impacting splicing was large but could be substantially reduced when combined with outlier splicing information from RNA-seq (Fig. 3c) . From our pool of candidate genes with splicing outliers, we looked at the proportion remaining after different filters (Fig. 3d) . We observed that, by limiting to genes relevant to the phenotype (Filter 2) and with a deleterious rare variant within 20 base pairs (bp) of the splicing junction (Filter 5), we were able to narrow down to only 0.14% of potential candidate genes (Filter 7). Overall, 32% of individuals with disease had at least 1 gene matching these criteria (Extended Data Fig. 5b) . Furthermore, genes selected after filtering carried more deleterious rare variants than unfiltered outliers, suggesting an enrichment of disease genes with compound heterozygous mutations (Fig. 3e) . Overall, the filtering steps reduced candidates to less than ten per individual on average (Fig. 3f) .
RNA-seq provides the ability to measure ASE. ASE can inform the presence of a large-effect heterozygous regulatory, splicing or nonsense variant, or epi-mutation, aiding the identification of candidate rare-disease genes and variants 7, [27] [28] [29] . Of all possible heterozygous sites (~10 5 and ~10 6 per sample for exome and genome, respectively), 10 4 variants had sufficient coverage for analysis
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(Extended Data Fig. 7a ). Independent of sequencing technology, we observed 10 3 sites displaying allelic imbalance with an allelic ratio ≤0.35 or ≥0.65. To highlight ASE events that might be disease-related, we focused on the subset of gene outlier ASE sites within the individuals with disease whom we studied when compared with all other rare-disease individuals and GTEx samples , missense (blue) and synonymous (yellow) mutations at different percentiles of gene expression. This is represented as the log odds ratio with 95% Wald confidence intervals using 931 samples. P values were calculated on the basis of the z-statistic. There was no adjustment for multiple testing. b, Impact of Z-score thresholds on number of outliers. Differences between under-and over-expression outliers were tested using a two-sided Wilcoxon rank sum test.
No adjustment for multiple testing. Vertical dashed lines indicate mean Z-score for n = 1 and n = 5 percentiles across all genes used in analysis (n = 14,988). For a and b, significance levels were: ****P ≤ 1 × 10
; ***P ≤ 1 × 10
; **P ≤ 1 × 10
; *P ≤ 5 × 10
. c, Proportion of under-expression outlier genes remaining after filters (n = 75 individuals with genetic information). Adding genetic information (rare variant within 10 kb upstream of the gene body) allows filtering down to 50% of the original set of outliers. Keeping only genes for which HPO information of the affected individual matches helps narrow down to less than 10% of candidates. For b and c, boxplots represent the median value, with lower and upper hinges corresponding to the 25th and 75th percentiles, and lower and upper whiskers extending from the hinge to the smallest and largest value that is at most 1.5× interquartile range of the hinge, respectively. d, Number of candidate genes at each filter for all individuals with genetic information (n = 75). Average number of candidate genes and s.d. are represented in black for each filter. Vertical bars were used to highlight filters that were used together at a particular instance. They were used only with more than one filter was applied. 
Rare variant
Number of genes We defined the proportion of one splice junction as the number of reads overlapping this junction divided by the total number of reads spanning all junctions from a common donor (or acceptor). b, Number of genes with at least 1 splicing outlier at different Z-score thresholds (n = 208 samples from PIVUS and rare-disease cohorts). c, Number of rare variants in each sample, in total, nearby junction and associated with a splicing outlier (n = 111 samples with genetic information). Rare variants were defined as variants with MAF ≤ 0.1%. d, Impact of different filters on splicing outlier discoveries (n = 75 individuals with disease with genetic information). e, We observed a significant increase (two-sided Wilcoxon test, P value 9.8 × 10
) in the median number of rare variants with CADD score ≥ 10 in the gene when filtering outliers with a rare variant within 20 bp of the junction and relevant to the disease phenotype (HPO match) (n = 109 samples with splicing outliers and genetic data). f, Number of candidate genes at each filter for all individuals with disease with genetic information (n = 75). Mean value and s.d. are represented in black for each filter. Vertical bars were used to highlight filters that were used together at a particular instance. They were used only with more than one filter was applied. For b, d and e, boxplots represent median value, with lower and upper hinges corresponding to the 25th and 75th percentiles, and lower and upper whiskers extending from the hinge to the smallest and largest value at most 1.5× interquartile range of the hinge, respectively.
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(Extended Data Fig. 7a ). We found an average of 94 ASE outliers per individual. We observed that the top 20 ASE outlier genes are enriched for overlap with HPO-associated genes per case, regardless of the filters applied to the extreme ASE genes and background genes (that is, pLI ≥ 0.9, Rare variant nearby, Rare variant with CADD score ≥ 10 nearby; Extended Data Fig. 7b ). We also tested whether ASE would allow us to identify deleterious variants that were over-represented as this may be a marker for compound events or haploinsufficiency. Here, we focused on rare deleterious variants where the alternative allele is more abundant than the reference allele (Extended Data Fig. 7c ). In total, 111 rare variants show allelic imbalance biased toward the deleterious alternative allele (96 splice and 15 stop-gain). Among them, one variant is in EFHD2, a gene coding for Ca 2+ adapter protein involved in B cell apoptosis, NF-kBmediated inflammatory response and immune cell activation and motility [30] [31] [32] [33] . The carrier of this event was diagnosed with idiopathic The number of candidate genes was obtained throughout different filters using genetic data, splicing outlier data and phenotypic data. Shape indicates if the causal gene is in the list of genes left after filtering for the displayed criteria (triangle, yes; circle, no). After filtering for splicing outliers with a deleterious rare splice variant within 20 bp of a splice junction and limiting the search to genes for which there is a link to phenotype (HPO match), one candidate gene was left, KCTD7. b, Sashimi plot of the proband and three controls of the splicing gain region in KCTD7. For the proband only (red track), we observed a splicing junction ahead of the annotated one in exon 3. c, cDNA gel from fibroblast cDNA of exons 2-4 of KCTD7 for the proband, her affected sibling and 3 unaffected controls (no independent replicate). Both for the proband and her affected brother, we observed two fragments of different sizes, corresponding to the alternative splice products induced by the splice-gain mutation. In control samples, only one fragment is observed, corresponding to the original transcript. Reads per kilobase of transcript, per million mapped reads (RPKM) represents the level of expression of KCTD7 for the samples displayed.
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Nature MediciNe cardiomyopathy, where accompanying symptoms (elevated inflammatory markers, Raynaud's disease and alopecia) are indicative of auto-immune issues. By integrating expression, splicing and ASE signals, we were able to identify and validate the causal gene in 6 of 80 independent individuals with disease (7.5%, 4 expression outliers, 2 splicing outliers), and identify candidate genes potentially linked to the disease phenotype (gene matching HPO terms for the symptoms of the proband) in 5 of 30 cases with candidate gene information (16.7%) (Extended Data Fig. 8a and Supplementary Table 1) . We did not find highly relevant candidate genes for 69 individuals (86%). Notably, candidates were identified for five neurological cases where blood is not assumed to be a representative tissue. Furthermore, we observed that for cases where a candidate gene set was provided based on previous literature, we had a higher percentage of overlaps with an RNA-based filtered gene set than a DNA-based filtered gene set (Extended Data Fig. 8b ).
Three cases exemplify the use of RNA-seq in causal gene identification. In the first case, of two brothers aged 4 and 5 years, each presented at 6 months with delayed motor milestones and hypotonia, which evolved to include spasticity, an ataxic gait and progressive loss of motor skills. Genome sequencing identified biallelic heterozygous pathogenic variants in the MECR gene present in both siblings: c.830+2dupT and c.−39G>C. Pathogenic variants in MECR are associated with mitochondrial enoyl CoA reductase protein-associated neurodegeneration (MEPAN), a rare disorder characterized by childhood-onset movement disorder, signal hyperintensity in the basal ganglia, optic atrophy and relatively preserved cognition. To date, only seven individuals with MEPAN have been reported in the literature 34 . The c.830+2dupT variant has been described previously 34 . After applying our pipeline on expression outliers, we found MECR as a candidate in both siblings in a list of 11 and 15 genes, respectively (with, respectively, 1 and 0 candidates left after the splicing pipeline, true positive rate (TPR) between 6.7% and 8.3%) (Extended Data Fig. 9a,b) . Without expression information, there were 245 and 302 genes (including MECR, and with 111 and 161 additional after the splicing-based pipeline) linked to the phenotype with a rare deleterious variant within 10 kb (TPR between 0.28% and 0.21%).
In a second case, a 12-year-old Hispanic female presented with developmental regression after typical development until age 18 months, manifesting with loss of milestones including head control and speech. Tremors developed at 21 months, and seizures at 22 months. She also suffered from occasional myoclonus. She has a 5-year-old brother with onset at 13 months of ataxia, autism, developmental delay, recurrent febrile seizures and absent speech. Without expression data, we were able to filter the number of candidate genes from 1,034 genes to 96 genes (with an additional 105 candidate genes from the expression-based side of the pipeline, TPR 0.49%), when looking only at genes associated with the phenotypes (from HPO terms 24 ) and containing rare variants within 20 bp of annotated junctions with a CADD score ≥ 10 (ref.
35
). The causal gene is missing from the most stringent filter because there are no rare deleterious variants within 20 bp of known junctions. Adding splicing outlier information from RNA-seq data left us with 1 gene (in addition to 7 filtered expression outliers, TPR 12.5%), KCTD7, containing a non-annotated junction in the affected sample (Fig. 4a , left panel). A synonymous mutation was found to be responsible for the creation of a splicing junction in this gene (p.V152V; Fig. 4b ). PCR with reverse transcription of RNA extracted from fibroblasts from exon 2-4 regions of the gene confirmed a difference in fragment size in the probands ( Fig. 4c and Source Data). In addition, this variant exhibited monoallelic expression toward the reference allele as a consequence of the premature splicing event.
In a third case, we reprocessed a solved case for which we had found an exon-skipping event in a previous study 8 . In this case, the patient presented with a sporadic form of spinal muscular atrophy. After filtering for splicing outliers (|Z-score| ≥ 2) and selecting only genes relevant to the symptoms (HPO), only 8 genes were left (Extended Data Fig. 10a ), ASAH1 being the strongest outlier, and for which we subsequently identified with Sanger sequencing a splice-loss mutation leading to the creation of a transcript, skipping exon 6 (Extended Data Fig. 10b ). While we obtained genetic data for many individuals in this study, this case demonstrated that use of RNA-seq alone can aid in disease gene identification.
In summary, the use of whole-blood RNA-seq in combination with variants and phenotype-relevant gene filters was able to identify the causal gene and variant(s) in 7.5% of individuals with disease or to further highlight candidate genes linked to phenotype in 16.7% of cases (see Methods). We recommend using our most stringent set of filters from splicing and expression outliers. As with exome sequencing, we expect this to be a baseline rate that will grow through ongoing case reanalysis 36, 37 . Similar to the utility of large databases of control exomes for Mendelian disease diagnoses 14, [38] [39] [40] , we demonstrated the utility of large control RNA-seq data sets to identify aberrant expression, splicing and ASE events in candidate rare-disease genes. Furthermore, this work demonstrates the utility of performing RNA-seq on peripheral blood, which is a readily available specimen type in clinical practice. Throughout our study, a trade-off needed to be found between strictly filtering the data and losing candidates of interest. It is worth noting that this combination of information is not expected to lead to the causal gene successfully in the following situations: first, if the causal gene is not expressed in the analyzed tissue; second, if the effects of the causal variant do not affect the expression of the gene; and third, if the filters are too strict. Therefore, expert evaluation remains to be required when prioritizing candidate genes using RNA-seq data. We can expect that combining information from multiple 'omics' sources will only further improve diagnosis of unsolved rare-disease cases in the future.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-019-0457-8. Whole-blood samples were collected and shipped in Paxgene RNA tubes or as isolated RNA for processing. Paxgene RNA tubes were processed manually per manufacturer's protocol and 1.0 μg RNA was used for further processing. Isolated total RNA was analyzed on an Agilent Bioanalyzer 2100 by pico RNA chip for RNA integrity number (RIN) quality check. Globin mRNA was removed using GLOBINclear before cDNA library construction. cDNA libraries were constructed following the Illumina TrueSeq Stranded mRNA Sample Prep Kit protocol and dual indexed. The average size and quality of each cDNA library was determined by Bioanalyzer and concentrations were determined by Qubit for proper dilutions and balancing across samples. On average, 20 pooled samples were run simultaneously on an Illumina NextSeq 500 (high-output cartridge). Pooled samples were run in 9 distinct sequencing runs: 2 runs generated 75-bp paired-end reads and 7 runs generated 150-bp paired-end reads. Output bcl files were converted to fastq files and demultiplexed using bcl2fastq v.2.15.0.4 from Illumina. Overall, we obtained around 50 million reads per sample (median 52 million ± 20 million ).
Reads were trimmed and adapters were removed using cutadapt v.1.11 (https://github.com/marcelm/cutadapt). Reads were then aligned to the reference human genome (hg19) with STAR v.2.4.0j (https://github.com/alexdobin/STAR/ releases/tag/STAR_2.4.0j). We used gencode v.19 for reference annotation (https:// www.gencodegenes.org/releases/19.html). We removed reads with a mapping quality under 30 and filtered duplicate reads with Picard Tools MarkDuplicates v.1.131 (http://broadinstitute.github.io/picard/). Gene-level and transcript-level quantifications were generated with RSEM v.1.2.21 (ref. 41 ) (https://github.com/ deweylab/RSEM/releases/tag/v1.2.21). Junction files generated by STAR were filtered: to consider a junction, a minimum of ten reads uniquely spanning were required. For faster processing of samples, we used GNU parallel 42 . Independent control cohorts for expression, splicing and ASE analyses. We used whole-blood transcriptome data of 909 samples from the DGN cohort 10 as well as 65 samples (age 70) from the PIVUS cohort 11 to serve as independent healthy controls for expression analysis and splicing, respectively. DGN samples are singleend 50-bp reads and PIVUS samples are 75-bp paired-end reads. Sequences were aligned, quantified and filtered following the same protocol used for individuals with rare disease and controls. We determined outlier ASE events at the gene level per individual by comparing our data with 620 individuals in GTEx v.7 (ref.
12
) across 48 tissues. ASE in GTEx was processed as in ref.
21
, and only sites with a minimum of 20 reads overlapping and not entirely monoallelically expressed were analyzed.
We tested the tolerance to different types of mutations (from ExAC) in function of the expression status in a single versus multiple tissues using a 2-sided Wilcoxon rank sum test on 620 individuals from GTEx v.7 across 22 tissues.
Disease gene lists.
Disease gene lists for neurology (n = 284 genes), ophthalmology (n = 380 genes), hematology (n = 50 genes) and musculoskeletal and orthopedics (n = 395 genes) and disease categories were obtained from curators for genes of interest with regard to the disease (Supplementary Table 4 ). We obtained OMIM gene lists (n = 3,766 genes) from https://omim.org/downloads/. Gene expression of disease genes in our samples was restricted to protein-coding genes.
Genetic data. Variant data were produced according to recommended protocols for exome or genome data. VCFs obtained from UDN were generated through Hudson Alpha and Baylor pipelines. In short, DNA read alignment was performed using BWA-mem v.0.7.12 (ref. 43 ) and variant calling was made using Genome Anaysis Tool Kit (GATK) v.3.3 (ref. 44 ). For samples from the Stanford Clinical Genomics Program (CGS), variant calling was performed using GATK v.3.4. We filtered variants according to the following criteria from previous studies • Exclude variants with call rate <0.80 (missing >20%)
We obtained genetic information for 112 samples (of 143; 54 from wholegenome sequencing, 58 from WES) (Supplementary Table 1 ). The number of LoF rare variants is variable across samples and institutions. We merged all VCF files from those different institutions and homogenized their format for further analysis. We used BEDtools (v.2.26.0-112-gd8c0fe4) 46 to filter for junction or gene with a rare variant within 20 bp of a tested splicing junction. We filtered for rare variants with MAF ≤ 0.1%. We kept the singletons in the analysis.
Genetic data annotation.
We annotated genetic data with allele frequency from the Genome Aggregation Database (gnomAD) 14 and CADD 35 scores using Vcfanno (v.0.2.7) 47 . We used CADD v.1.3 and gnomAD release v.2.0.2.
Ancestry inference. VCF files were processed for ancestry inference using BCFtools v.1.8 as follows. They were normalized (fixing strand flips and left aligning indel records) and merged. We then subset this file to only variants in exonic regions, and filtered out variant with >25% missingness. Missing variants were set to homozygous reference. A total of 2,666 variants remained after filtering.
To perform ancestry inference, we used all individuals from 1000 Genomes phase 3 version 5 populations. For computational feasibility, we used genotypes from chromosomes 1, 4, 12, 15, 16 and 19. We used the prcomp function in R to extract principal components and plotted the first three principal components.
Expression level normalization. We filtered out genes for which less than 50% of samples from each origin (that is, rare-disease individuals and unaffected family members sequenced in-house, external controls) had TPM > 0.5 and/ or variance equal to 0. This resulted in 14,988 genes being retained in the data set. We performed surrogate variable analysis (SVA) using the 'two-step' method on a centered and scaled matrix of log 10 -transformed (log 10 (TPM + 1)) RNAseq count data output by RSEM 41 . We did not provide any known covariates to SVA. To control for non-linearity in uncorrected gene expression data, we added regression splines for the top 2 surrogate variables (SVs) significantly associated with batch and institution (P < 1 × 10 −30 from univariate linear regression of batch and institution against all significant SVs), removing the untransformed SV in each case. Linear regression splines had knots positioned at every 1.66% of samples, resulting in approximately 17 individuals per region-which is around the average number of individuals in each batch sequenced in-house (Extended Data Fig. 3 ). Significant SVs and regression splines were then used as covariates in a regression model. The residuals of this model were centered and scaled to generate Z-scores for use in all subsequent analyses using gene expression data.
We tested the impact of adding splines in the model using a per-gene likelihood ratio test comparing linear regression model fit with and without regression splines. We used 1,052 samples and corrected P values for multiple testing (Benjamini-Hochberg adjustment).
Global outliers.
To control for potential residual technical artifacts impacting outlier expression, we removed samples for which 100 or more genes had normalized expression values of |Z-score| > 4 after SVA correction (54 samples). We tested the model described in Fig. 2 for several global outlier thresholds and observed a similar enrichment profile.
Gene expression outlier enrichment analyses. We used the union of DGN samples and healthy family members that passed the global outlier criteria as the control set (n = 899 and n = 32 individuals, respectively). We assessed enrichment for case outliers at increasingly stringent percentiles of gene expression in genes intolerant to mutations using a logistic regression model. As features in this model we used ExAC gene constraint metrics for LoF, missense and synonymous mutations 16 . For each gene in the data set that had ExAC gene constraint metrics (n genes = 10,605), we calculated a binomial outcome variable corresponding to the proportion of case expression outliers found in each gene: Y i ~ B(n i ; p i ), where n i is the number of outlier samples in gene i at a given percentile tested (the number of 'trials'), and p i is the proportion of case outlier samples (which can be thought of as the probability of 'success' (or all outliers being case outliers) for gene i). Then, we modeled the relationship between the observed proportion of cases for each gene, and the corresponding gene constraint Z-score from ExAC. Specifically, we wanted to find Pr(Y i = AllCases/X i ), where X i is the gene constraint Z-score for gene i. We assessed the effect of X using logistic regression: logit(p(X)) = β 0 + β 1 ×. A positive β 1 value indicates that a step change in constraint metric X (toward genes less tolerant to mutations) is associated with an increase in the log odds of Y i = 1 (that is, all outliers being case outliers). A separate model was fit for each mutation class. We reported results as the log odds (±1.96 × s.e.m.) associated with each feature for each percentile. P values were calculated based on the z-statistic.
RIVER analysis. RIVER is a hierarchical Bayesian model to infer rare variants of their regulatory effects. Compared with other variant scoring methods, RIVER has the advantage of using both genomic information and transcriptome information 21 . We used GTEx v.7 whole-genome sequencing and cross-tissue RNA-seq data as training data for the model. The trained model (with learned parameters) is subsequently applied on UDN data to predict effects of rare variants. The model uses rare variants and the genomic annotations at those variants as predictors, and uses RNA status (in this case outlier status based on total gene expression levels) as the target/response variable. Rare variants here are defined as those with Letters Nature MediciNe MAF < 0.01 in 1000 Genomes Project phase III, with all populations combined. For variants in GTEx we additionally require MAF < 0.01 within the GTEx cohort itself, and for variants in the rare-disease samples we additionally require MAF < 0.02 within the rare-disease samples themselves. We considered all rare variants within 10 kb of genes (from 10 kb before transcription start site to 10 kb after transcription end site). Overall, there was a median of two rare variants per gene for GTEx subjects and rare-disease subjects. ), CpG content, GC content, chromHMM 53 and Encode chromatin-openness track. We selected these features based on their earlier evidence of association with regulatory effects 21 . Features were aggregated over each gene and individual pair, using either max(), min() for quantitative features, or any() for categorical features. Expression outliers (response variables) were defined as those with |Z-score| > 2. Z-scores were calculated based on total gene expression level reads per kilobase of transcript, per million mapped reads (RPKM) from RNA-seq. In addition, for GTEx training data, gene expression levels were corrected by PEER 54 to remove technical artifacts and major common-variant expression quantitative trait loci (eQTL) effects were also removed. Z-scores for GTEx are median over all available tissues 21 . Junction coverage ratios. Reference junctions were derived from Gencode v.19 annotation files on known protein-coding genes (142,246 in 14,296 genes). For each junction donor (then acceptor), all possible acceptors (then donors) were screened in the sample junction files. The distribution of reads spanning those junction sets was evaluated by calculating the set ratios (Fig. 3a) . We restricted the analysis to junctions for which several acceptors (donors) were associated to one donor (acceptor). In total, 13,109 groups of junctions were generated. In total, 34,060 junctions in 6,261 protein-coding genes across all samples fulfilled those criteria. We performed the analysis on all PIVUS samples (n = 65) and rare-disease samples (n = 143).
Splicing data normalization and analysis. We used the union of PIVUS samples (n = 65) and healthy family members (n = 49) as a control set together with all of the cases samples (n = 94). To remove possible noise, and to allow missing values imputation, we removed junctions for which there were no more than 30 samples with data in the junction group. We analyzed coverage ratios for a total of 25,612 junctions.
Missing values in junction coverage ratios were imputed using missMDA R package. Principal component analysis was then performed using prcomp R package. We regressed out principal components accounting for 95% of the variation in our imputed dataset (176 principal components). We then put back original missing values in the data set and derived Z-scores used in the outlier analysis. We looked at the correlation pattern between the first ten principal components and known covariates from our data set. In brief, principal component 1 mainly separated the source of the data (UDN, CGS, CHEO or PIVUS). Principal component 2 highlighted differences between the first batch and the other batches. Overall, we observed some level of correlation between all known covariates and the principal components that were regressed out from the data.
We tested the impact of our filters on the median number of rare variants with CADD score ≥ 10 with a 2-sided Wilcoxon rank sum test on all samples with splicing outliers and genetic information (n = 74).
ASE.
ASEReadCounter 55 v.3.8-0-ge9d806836 from Genome Anaysis Tool Kit 56 was run on single nucleotide variants from VCFs provided by the UDN, CHEO and CGS and corresponding RNA-seq data, using all samples for which we had genetic information (n = 112). Only sites with a minimum read depth of 10, mapping quality of 10 and base quality of 2 were integrated in the analysis. For a gene to be considered with ASE, we required that at least 5 samples had heterozygous sites in the gene, that the heterozygous site was covered by at least 20 reads for the individual and with an imbalanced allelic ratio ( ≥0.65 or ≤0.35). We eliminated total mono-allelic expression from the analysis (that is, allelic ratio = 0 or 1).
To detect ASE outliers, we restricted our analysis to sites and genes common to our samples and GTEx data set including 11,224 genes and 87,739 sites, subject to the same site filters above. After this step, 108 individuals were left. We scaled the reference ratios for all sites within a gene across samples to obtain Z-scores per site. To summarize GTEx data per individual, we considered the maximum ratio (|0.5 − reference ratio|) across all tissues for which the individual had data at that site. Then, for each individual, we selected the top N genes by |Z-score| as ASE outliers. We assessed the overlap of this set of genes with the genes associated with that individual's listed HPO terms, as well as the parent and child terms. To determine whether the overlap of ASE outliers with HPO-associated genes was significant, we selected 20 genes at random for each individual and assessed the overlap with the same HPO-associated genes. This was repeated 100 times. We then layered in additional filters, and took the top N most extreme ASE genes with a pLI > 0.9 or with a nearby rare variant with that individual, and, finally, a nearby deleterious (CADD ≥ 10) rare variant. In each instance, we matched the background for that filter, thereby comparing the overlap for extreme ASE + pLI > 0.9 with HPO-associated genes with the overlap seen in a random background of genes, also with pLI > 0.9, and the same with the rare variant criteria.
Phenotypic data. For each individual for whom we had RNA-seq data (n = 94), we also obtained HPO terms corresponding to the symptoms of the affected individual. We extended this list of HPO terms to terms that were hierarchically one level lower (child terms), one level higher (parent terms) or alternative terms for the same phenotype. To do so, we used the Human Phenotype Ontology (HPO, downloaded 10-23-18) 22 (http://human-phenotype-ontology.github.io/downloads. html). To link HPO terms to genes, we used the genes to phenotype and phenotype annotation files provided by the Human Phenotypic Ontology. Diagnostic rate. We labeled 'solved' the individuals for which we found candidates from RNA-seq data for which the causal mutation was found and validated. To evaluate the number of individuals for which we had strong candidates, we took a subset of 30 individuals from the same institutions for which we obtained a list of candidate genes from curators. If any of those candidates were in the final set of filtered genes, they were labeled as 'strong candidate' . Individuals for whom no strong candidate genes were found after analyzing RNA-seq data were labeled 'no candidate' .
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
UDN data are accessible through the UDN Gateway and through dbGaP entry at phs001232.v1.p1. DGN RNA-seq data are available by application through the NIMH Center for Collaborative Genomic Studies on Mental Disorders. Instructions for requesting access to data can be found at https://www. nimhgenetics.org/access_data_biomaterial.php, and inquiries should reference the 'Depression Genes and Networks study (D. Levinson, PI)' . The GTEx Analysis v.7 release allele-specific expression data are available from dbGaP (dbGaP Accession phs000424.v7.p2). PIVUS RNA-seq data are accessible on the European GenomePhenome Archive (EGAS00001003583). The Care4Rare data are available through Genomics4RD.
Code availability
Code for running the analysis and producing the figures throughout the manuscript is available at https://github.com/lfresard/blood_rnaseq_rare_disease_ paper. Our pipeline to highlight candidate variants is available at https://github. com/lfresard/blood_rnaseq_rare_disease_paper/blob/master/pipeline.md ). Analysis performed on 620 individuals from GTEx v.7 across 22 tissues. Boxplots represent median value, with lower and upper hinges corresponding to the 25th and 75th percentiles, and lower and upper whiskers extend from the hinge to the smallest and largest value at most 1.5× interquartile range of the hinge, respectively. Genes that are expressed in multiple tissues tend to be more sensitive to missense and LoF mutations. d, Number of LoF intolerant genes stratified by expression level in blood. We considered genes with pLI score ≥ 0.9 as LoF intolerant. , in decreasing order, across all genes in the dataset (n = 14,988) after correcting data using significant SVs with regression splines, compared to correcting data using significant SVs without regression splines. Mean change in R 2 is 0.036 (s.d. = 0.025).
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Extended Data Fig. 4 | Impact of the number of controls on loss-of-function intolerance enrichment. a, Enrichment of case (red, n = 64) underexpression outliers in LoF sensitive genes as we increase the number of controls (7,600 random subsets for each sample size indicated in legend). This enrichment was not observed for rare disease family member controls (gray, n = 34). b, Benjamini & Hochberg adjusted −log 10 P value associated with the enrichment at different number of controls (two-sided t-test, n = 64 cases). Horizontal line indicates 0.05 significance cutoff. The P values are decreasing as we increase the number of controls. When switching cases for controls (gray) we observed significant negative log odds when using the a smaller number of controls, but this trend disappeared when using the full set of 900 controls. For a and b, Boxplots represent median value, with lower and upper hinges corresponding to the 25th and 75th percentiles, and lower and upper whiskers extend from the hinge to the smallest and largest value at most 1.5× interquartile range of the hinge, respectively. By combining several layers of filters we are drastically reducing the number of candidate genes but also the number of samples for which we have candidates. We recommend to relax filter stringency after looking at sets of genes that match the most stringent criterion. a, Expression outliers. After filtering for outlier genes matching HPO terms, with a deleterious rare variant within 10 kb, we observed less than 2.6% of samples with over 25 candidate genes. b, Splicing outliers. When keeping only genes with HPO match, and a deleterious rare variant with 20 bp of the outlier junction, we observed less than 1.3% of samples with more than five candidate genes.
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Extended Data Fig. 6 | Correction for batch effects -Splicing data. Analyses performed on 65 PIVUS samples and 143 rare disease samples. a, Plot of first two principal components (PCs) run on uncorrected splicing ratio data. Samples are coloured by batch. We observed that PC1 was separating PIVUS controls samples (left) from rare disease samples (right). b, Plot of first two PCs on splicing ratios after regressing out PCs explained up to 95% of the variance in the data. Batches were no longer separated on the first PCs. c, Correlation between known covariates 10 first PCs. We observed that PC1 is highly correlated with the batch, whereas PCs 2 and 3 separated samples from one institution (batch 1, CHEO) from others. We also observed that PC1 is highly correlated with RIN, highlighting differences in quality across samples. , two-sided Wilcoxon test). For a and b, Boxplots represent median value, with lower and upper hinges corresponding to the 25th and 75th percentiles, and lower and upper whiskers extend from the hinge to the smallest and largest value at most 1.5× interquartile range of the hinge respectively. c, Rare deleterious variants are biased toward the alternative allele across all samples. A stop-gain variant was highly expressed in EFHD2 for one sample where there were matching symptoms.
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Extended Data Fig. 8 | Diagnostic rate after analysis of 80 distinct cases. a, Overview of cases. Solved: causal gene found and further validated. Strong candidate: Strong candidate after RNA-seq analysis (out of a subset of 30 affected individuals for which we have prior candidate genes information from literature). Unsolved: Other cases for which further investigation is needed. b, Percentage of cases for which prior candidate gene is in final set of filtered genes (outlier with deleterious rare variant in a gene linked to symptoms). Analysis was performed only on a subset of 30 cases for which we have prior candidate gene information and for which we have genetic information. Shuffling candidates corresponds to the percentage of cases for which we observe a prior candidate genes in the most stringent gene list when shuffling gene lists across individuals (10,000 permutations). On average, no match is found. Shuffling genes correspond to the percentage of prior candidate genes we observed within the final set of DNA-only filters when sampling from this list a matched number of genes corresponding to the expression filters. Average matched percentage is 4.1% after 10,000 permutations. Real data corresponds to the percentage of cases for which we found a candidate gene in the most stringent RNA-based filter set. We find a match for 7 affected samples out of 30, that is, 25.9 % of cases. There is significantly more match in real data in comparison to permuted data (two-sided Wilcoxon rank sum test, P value < 10 -5 ). Boxplots represent median value, with lower and upper hinges corresponding to the 25th and 75th percentiles, and lower and upper whiskers extend from the hinge to the smallest and largest value at most 1.5× interquartile range of the hinge, respectively. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Sample size
The sample size was based on the availability of undiagnosed cases for which we had blood data. This paper is showing that comparing those cases to large control cohorts can lead to diagnosis. We used controls sets for which we had blood transcriptome data and varied sample size to assess its impact on observed results. We investigated 94 cases across 16 diverse disease categories, using over 1500 controls. This is more samples than any publication on the subject to date.
Data exclusions To control for potential residual technical artifacts impacting outlier expression, we removed samples for which 100 or more genes had normalized expression values of |Z-score| > 4 after SVA correction (54 samples). In general, samples were excluded if not meeting QC requirements specific to analyses. Sample size used are reported for each analysis.
Replication
Cases for which the diagnosis is described as validated were confirmed through independent experiments such as Sanger sequencing or RT-PCR and reflect cases for which the gene was previously known in the literature to be involved in similar phenotypes. All attempts for replication were successful.
Randomization RNA-sequencing runs were performs based upon data availability. Family members were grouped on the same run. We corrected the data for batch effects (as described in the manuscript) and show the correlation of those batches to the sequencing run before and after correction.
Blinding
No blinding was performed in the context of our study. Phenotypes and family relationship were needed for appropriate diagnostic of the affected samples.
Reporting for specific materials, systems and methods 
Recruitment
For the UDN, the recruitment is based on the following criteria from to the consortium (https://commonfund.nih.gov/diseases): -the applicant does not have a diagnosis that explains the objective findings.
-the applicant or legal guardian agrees to the storage and sharing of information and biomaterials in an identified fashion amongst the UDN centers and in a de-identified fashion to research sites beyond the network. For the CGS, we requested de-identified specimens and/or subsequently generated data from participants (and, when applicable, their family members) that have been enrolled in the Stanford Clinical Genomics Program's research pilot pro gram. In this research pilot program, participants were already consented to be involved in research and disease (Stanford IRBapproved protocol #23066) and were referred from healthcare providers at Stanford. These referring physicians have expertise in heritable disorders, and patients selected for the pilot program have conditions with suspected genetic etiology, based on the physician's evaluation of specific clinical or differential diagnosis as well as family history. We requested deidentified specimens and/or subsequently generated data for the purposes of development of RNA seq and other computational/experimental approaches aimed at improving the diagnostic yield of genomic sequencing (Stanford IRB-approved protocol # 38046). Appropriate Biobank/ laboratory staff responsible for processing the biobank specimens provided de-identified specimens/data to our research group. The CHEO patient recruitment was performed under the Care4Rare Canada consortium protocol (http://care4rare.ca/).
We analyzed all samples received that passed our QC, independently of the disease type or the origin of the sample.
